xMAP | GenomeWeb

xMAP

NEW YORK (GenomeWeb) — Luminex reported after the close of the market Monday a 12 percent spike in third quarter revenues driven primarily by growth in assay sales across all major product categories.

NEW YORK (GenomeWeb News) – A federal court has dismissed claims against Luminex that had alleged patent infringement.

NEW YORK (GenomeWeb News) – Combinatorial chemistry systems firm Irori Technologies is suing Luminex accusing the Austin, Texas-based firm of infringing three patents with its xMAP and xTAG technologies.

This article was originally posted on Sept. 12.
Luminex has no plans to acquire any new businesses or companies at this time, its CEO Patrick Balthrop said at an investment conference last week.

Luminex's recent decision to reduce its workforce by 5 percent, close an office in Australia, and seek a buyer for its newborn screening business, was in part influenced by its attempt to obtain US regulatory clearance for its NeoPlex4 test, according to the firm's CEO.

Natural Molecular Testing created a stir in the marketplace last week when it announced it would be converting its pharmacogenetic test services to a new panel based on Luminex's xMAP multiplex bead array technology.

Natural Molecular Launches Personalized Rx Cardiac Test on Luminex xMAP

The story has been updated to include comments from GenMark.

NEW YORK (GenomeWeb News) – Luminex and Natural Molecular Testing have entered into a multiyear collaboration and licensing deal, resulting in a comprehensive personalized medicine panel.

Luminex is developing an automated, handheld, battery-powered diagnostic system based on its xMAP technology to administer both molecular and immunoassays to help diagnose soldiers or provide biosurveillance data at the point of need, the company said this week.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.